levodopa has been researched along with Nerve Degeneration in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (16.35) | 18.7374 |
| 1990's | 31 (29.81) | 18.2507 |
| 2000's | 42 (40.38) | 29.6817 |
| 2010's | 12 (11.54) | 24.3611 |
| 2020's | 2 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D | 1 |
| Betrouni, N; Carrière, N; Chupin, M; Defebvre, L; Devos, D; Kuchcinski, G; Lopes, R; Moreau, C; Rolland, AS; Viard, R | 1 |
| Adlard, PA; Billings, JL; Bush, AI; Doble, PA; Finkelstein, DI; Gordon, SL; Hare, DJ; Rawling, T | 1 |
| Müller, T | 2 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Chen, CY; Chen, IJ; Chen, YL; Hsiao, IT; Lin, KJ; Lu, CS; Wang, HL; Weng, YH; Yeh, TH | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C | 1 |
| Aguiar, PM; Barsottini, OG; Borges, V; Felício, AC; Ferraz, HB; Godeiro-Junior, C; Silva, SM | 1 |
| Barchak, AG; Busanello, EN; Camargo, D; Carrion, MJ; da Costa, JC; Dalbem, A; de Mello Rieder, CR; de Sousa Miguel, SR; dos Santos, EF; Miglioranza, A; Rosa, C; Saute, J; Vargas, CR; Wajner, M; Zanatta, A | 1 |
| Barman, PK; Borah, A; Mohanakumar, KP; Pandey, M; Usha, R; Varghese, M | 1 |
| Blume, SR; Cass, DK; Tseng, KY | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
| Bernardi, G; Berretta, N; Guatteo, E; Lipski, J; Mercuri, NB; Nistico, R | 1 |
| Arning, E; Bottiglieri, T; Nunbhakdi-Craig, V; Sontag, E; Sontag, JM; Wasek, B | 1 |
| Ankaralı, H; Gunal, DI; Mollahasanoğlu, A; Ozen Barut, B; Turkmen, C | 1 |
| Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT | 1 |
| Arima, K; Baker, M; Delisle, MB; Ghetti, B; Hutton, ML; Kobayashi, T; Komure, O; Kuno, S; Mizuno, Y; Murrell, JR; Rascol, O; Soulages, X; Sunohara, N; Tsuboi, Y; Uitti, RJ; Wszolek, ZK; Yasuda, M | 1 |
| Geser, F; Wenning, GK | 1 |
| Delfino, MA; Douhou, A; Ferrario, JE; Gershanik, OS; Murer, MG; Raisman-Vozari, R; Stefano, AV; Zbarsky, V | 1 |
| Budrewicz, S; Góral, M; Koszewicz, M; Podemski, R; Słotwiński, K; Turek, T | 1 |
| Benecke, R; Classen, J; Grossmann, A; Kunesch, E; Wolters, A | 1 |
| Kuhn, W; Müller, T; Renger, K | 1 |
| Birman, S; Coulom, H | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Hefter, H; Hueber, R; Jost, WH; Leenders, KL; Müller, T; Odin, P; Schwarz, J | 1 |
| Farsang, M; Kovács, T; Szirmai, I; Takáts, A | 1 |
| Morgan, J; Sethi, KD | 1 |
| Kim, MN; Kim, YM; Lee, JJ; Lee, MK | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q | 1 |
| Lang, AE | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Kadota, S; Li, X; Matsumoto, K; Murakami, Y; Tezuka, Y; Wu, Y | 1 |
| Brown, JM; Buzas, B; Candeletti, S; Cox, BM; Di Benedetto, M; Fantin, M; Guerrini, R; Marti, M; Mela, F; Morari, M; Reinscheid, RK; Romualdi, P; Salvadori, S; Simonato, M; Witta, J; Zucchini, S | 1 |
| Baltazar, G; Carvalho, CM; Duarte, EP; Saavedra, A; Santos, P | 1 |
| Giasson, BI; Ischiropoulos, H; Lynch, DR; Mazzulli, JR; Mishizen, AJ; Nagatsu, T; Nakashima, A; Ota, A; Thomas, SA | 1 |
| Colebrooke, RE; Emson, PC; Humby, T; Lynch, PJ; McGowan, DP; Xia, J | 1 |
| Abreu, P; Afonso-Oramas, D; Barroso-Chinea, P; Cruz-Muros, I; González, MC; Hernández, TG; Rodríguez, M | 1 |
| Mash, DC; Papapetropoulos, S | 1 |
| Brachet, P; Damier, P; Henry, V; Lescaudron, L; Paillé, V | 1 |
| Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R | 1 |
| Chalimoniuk, M; Langfort, J | 1 |
| Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Urbanavicius, J; Wonnacott, S | 1 |
| Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C | 1 |
| Halliday, GM; Hardman, CD; Karaconji, T; Murphy, KE | 1 |
| Cagniard, B; Chen, L; Chi, W; Ding, Y; Hastings, TG; Kang, UJ; Mortimer, A; Van Laar, AD; Zhuang, X | 1 |
| Bernson, M; Darmopil, S; de Ceballos, ML; Moratalla, R; Muñetón-Gómez, VC | 1 |
| Destée, A; Fénelon, G; Kreisler, A; Mastain, B; Tison, F | 1 |
| Belton, P; Davison, AJ; Wilson, BD | 1 |
| Cohen, G | 1 |
| Ciannella, L; Dell'Aria, V; Melone, MA | 1 |
| Agid, Y; Bonnet, AM; Gouider-Khouja, N; Pichon, J; Vidailhet, M | 1 |
| Cooper, JM; Daniel, SE; Marsden, CD; Schapira, AH | 1 |
| Chouinard, G; Miller, R | 1 |
| Asanuma, M; Edamatsu, R; Kohno, M; Mizukawa, K; Mori, A; Ogawa, N | 1 |
| Aotsuka, A; Asahina, M; Hirayama, K; Inoue, O; Shinotoh, H; Suhara, T; Tateno, Y; Yamazaki, T | 1 |
| Agid, Y; Faucheux, BA; Hauw, JJ; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Levy, R; Obeso, JA; Villares, J | 1 |
| Aquilonius, SM; Hartvig, PG; Långström, B; Tedroff, J | 1 |
| Kraus, PH | 1 |
| Barzilai, A; Melamed, E; Offen, D; Shirvan, A; Zilkha-Falb, R; Ziv, I | 1 |
| Cooper, JM; Daniel, SE; Gash, MT; Gu, M; Marsden, CD; Quinn, NP; Schapira, AH; Wenning, GK | 1 |
| Bakke, SJ; Nyberg-Hansen, R; Shepherd, GM; Tauböll, E | 1 |
| Epstein, CJ; Khan, U; Mena, MA; Przedborski, S; Sulzer, D; Togasaki, DM | 1 |
| Calne, DB; Caselli, RJ; Forno, LS; Hornykiewicz, O; Howard, FM; Kish, SJ; Maraganore, DM; Muenter, MD; Okazaki, H; Snow, BJ | 1 |
| Brin, MF; Jenner, PG | 1 |
| Brooks, D; Jenner, P; Olanow, CW | 1 |
| Chase, TN; Oh, JD; Vaughan, CL | 1 |
| Foster, OJ; Kingsbury, AE; Marsden, CD | 1 |
| Abercrombie, ED; Miller, DW | 1 |
| Björklund, A; Dunnett, SB | 1 |
| Tedroff, JM | 1 |
| Agid, Y; Bédard, MA; Dubois, B; Duchesne, N; Masson, H; Pillon, B | 1 |
| Freed, WJ; Kishikawa, M; Takashima, H; Tsujihata, M | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A | 1 |
| Hirsch, EC | 1 |
| Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK | 1 |
| Andren, PE; Gunne, L; Svenningsson, P | 1 |
| Arai, N; Fujita, K; Furukawa, N; Goshima, Y; Misu, Y; Miyamae, T; Ohshima, E; Sasaki, Y; Suzuki, F | 1 |
| Eriksson, B; Holmberg, B; Ingvarsson, P; Johnels, B; Rosengren, L | 1 |
| Bannister, R | 1 |
| Klawans, H | 1 |
| Finn, BW; Mendez, JS | 1 |
| Murphy, MJ | 1 |
| Ljungberg, T; Ungerstedt, U | 1 |
| Trolin, GG | 1 |
| Birkmayer, W; Danielczyk, W; Neumayer, E; Riederer, P | 1 |
| Dufresne, JJ; Probst, A | 1 |
| Creese, I; Iversen, SD | 1 |
| Charlton, CG; Crowell, B | 1 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Bannister, R; Brooks, DJ; Frackowiak, RS; Ibanez, V; Lees, AJ; Marsden, CD; Mathias, CJ; Playford, ED; Quinn, N; Sawle, GV | 1 |
| Klein, AT; Langford, HG; Montani, M; Subramony, SH | 1 |
| Black, CK; Schmidt, CJ; Taylor, VL | 1 |
| Rinne, JO | 1 |
| Aceves, J; Floran, B; Hernandez, S; Mariscal, S; Martinez-Fong, D; Sierra, A | 1 |
| Melamed, E | 1 |
| Gibb, WR; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Ando, S; Inose, T; Miyakawa, K; Miyakawa, M; Mizushima, S; Oyanagi, S | 1 |
| Perquin, WV; Van Leeuwen, RB | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
19 review(s) available for levodopa and Nerve Degeneration
| Article | Year |
|---|---|
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.
Topics: Aging; Animals; Antioxidants; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Inactivation, Metabolic; Levodopa; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2013 |
Motor complications, levodopa metabolism and progression of Parkinson's disease.
Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission | 2011 |
L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Dopamine; Dopaminergic Neurons; Humans; Levodopa; Mitochondria; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2011 |
Multiple system atrophy.
Topics: Antiparkinson Agents; Ataxia; Humans; Hypotension, Orthostatic; Levodopa; Multiple System Atrophy; Nerve Degeneration; Neuroglia; Physical Therapy Modalities; Randomized Controlled Trials as Topic | 2003 |
Is levodopa toxic?
Topics: Animals; Dose-Response Relationship, Drug; Homocysteine; Humans; Levodopa; Nerve Degeneration; Neurotoxins; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2004 |
[Clinical features of corticobasal degeneration].
Topics: Aged; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Diagnosis, Differential; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Degeneration; Neurodegenerative Diseases; Parkinson Disease | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Homocysteine and Parkinson's disease: a dangerous liaison?
Topics: Brain; Brain Diseases, Metabolic; Causality; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Nerve Degeneration; Parkinson Disease | 2007 |
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
Topics: Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Psychoses, Substance-Induced; Receptors, Cholinergic; Receptors, Dopamine; Schizophrenia | 1993 |
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Neostriatum; Nerve Degeneration; Substantia Nigra; Tomography, Emission-Computed | 1996 |
Early diagnosis in Parkinson's disease--limitation of biochemical markers and instrumental methods.
Topics: Apomorphine; Biomarkers; Cell Death; Corpus Striatum; Diagnostic Imaging; Electrophysiology; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Substantia Nigra; Time Factors | 1996 |
Levodopa neurotoxicity: experimental studies versus clinical relevance.
Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Survival; Dopamine; Humans; Levodopa; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Reactive Oxygen Species; Substantia Nigra | 1998 |
Dopamine agonists and neuroprotection in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Levodopa; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease | 1998 |
Prospects for new restorative and neuroprotective treatments in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Death; Gene Transfer Techniques; Humans; Levodopa; Mutation; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 1999 |
Functional consequences of dopaminergic degeneration in Parkinson's disease.
Topics: Adaptation, Physiological; Brain; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Receptors, Dopamine D2 | 1999 |
Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
Topics: Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Substantia Nigra | 2000 |
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1975 |
Nigral degeneration in Parkinson's disease in relation to clinical features.
Topics: Corpus Striatum; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Neurologic Examination; Parkinson Disease; Selegiline; Substantia Nigra | 1991 |
Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Topics: Corpus Striatum; Dopamine; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Parkinson Disease; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission | 1990 |
5 trial(s) available for levodopa and Nerve Degeneration
| Article | Year |
|---|---|
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Cocaine; Corpus Striatum; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.
Topics: Acute Disease; Cholinergic Antagonists; Cognition Disorders; Corpus Striatum; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Middle Aged; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Scopolamine; Severity of Illness Index; Substantia Nigra; Syndrome; Time Factors; Trihexyphenidyl | 1999 |
CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Diagnosis, Differential; Discriminant Analysis; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Neurofilament Proteins; Parkinsonian Disorders; Spinal Puncture; Supranuclear Palsy, Progressive | 2001 |
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Pergolide and selegiline for Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Pergolide; Phenethylamines; Selegiline | 1989 |
80 other study(ies) available for levodopa and Nerve Degeneration
| Article | Year |
|---|---|
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes | 2020 |
Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Brain; Dyskinesia, Drug-Induced; Female; Gray Matter; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease | 2021 |
l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopaminergic Neurons; Humans; Iron; Iron Overload; Levodopa; Mice; Mice, Transgenic; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2019 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
(R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
Topics: Animals; Cell Survival; Dopaminergic Neurons; Gene Expression Regulation; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Motor Activity; Nerve Degeneration; Neurogenesis; Protein Serine-Threonine Kinases; Substantia Nigra | 2016 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Models, Animal; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2009 |
Clinical features of dystonia in atypical parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Dystonia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2008 |
Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
Topics: Analysis of Variance; Case-Control Studies; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Nerve Degeneration; Parkinson Disease; Reference Values; Statistics, Nonparametric; Vitamin B 12 | 2009 |
Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Huntington Disease; Hydroxyl Radical; Lameness, Animal; Levodopa; Male; Mitochondria; Nerve Degeneration; Neurotoxins; Nitro Compounds; Oxidative Phosphorylation; Oxidative Stress; Propionates; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
Topics: Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Forelimb; Hypokinesia; Lameness, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurologic Examination; Parkinsonian Disorders; Predictive Value of Tests; Sensitivity and Specificity; Substantia Nigra | 2009 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain.
Topics: Animals; Antiparkinson Agents; Brain; Cell Line, Tumor; Dopaminergic Neurons; Humans; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroblastoma; Phosphorylation; Primary Cell Culture; Protein Phosphatase 2; tau Proteins | 2012 |
Clinical and cognitive profiles of patients with both Parkinson's disease and essential tremor.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antiparkinson Agents; Attention; Cognition; Cognition Disorders; Essential Tremor; Executive Function; Female; Humans; Levodopa; Male; Memory; Middle Aged; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Primidone; Space Perception | 2013 |
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antiparkinson Agents; Carbidopa; Catechin; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluoresceins; Glial Fibrillary Acidic Protein; Hippocampus; Hydroxybenzoates; In Vitro Techniques; Kainic Acid; Levodopa; Male; Methylation; Mice; Nerve Degeneration; Neurons; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors; Tyrosine | 2013 |
Clinical and genetic studies of families with the tau N279K mutation (FTDP-17).
Topics: Adult; Antiparkinson Agents; Chromosomes, Human, Pair 17; Dementia; DNA; Founder Effect; France; Frontal Lobe; Humans; Japan; Levodopa; Male; Microsatellite Repeats; Molecular Biology; Mutation; Nerve Degeneration; Parkinson Disease; Penetrance; tau Proteins; Temporal Lobe; United States | 2002 |
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Injections, Intraventricular; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Time Factors; Tyrosine 3-Monooxygenase | 2003 |
[Cortico-basal degeneration: the rare form of tau protein disease].
Topics: Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Nerve Degeneration; tau Proteins | 2003 |
Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Corpus Callosum; Diagnosis, Differential; Electromyography; Humans; Levodopa; Magnetic Resonance Imaging; Magnetoencephalography; Middle Aged; Motor Cortex; Multiple System Atrophy; Muscle, Skeletal; Nerve Degeneration; Nerve Net; Neural Inhibition; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2004 |
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Chromatography, High Pressure Liquid; Electrophysiology; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Conduction; Parkinson Disease; Sural Nerve | 2004 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanogaster; Electron Transport Complex I; Insecticides; Levodopa; Locomotion; Melatonin; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenotype; Rotenone | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Inhibition of dopamine biosynthesis by tetrahydropapaveroline.
Topics: Adrenal Medulla; Animals; Antioxidants; Cattle; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Levodopa; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; PC12 Cells; Rats; Tetrahydropapaveroline; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Treatment of progressive supranuclear palsy and corticobasal degeneration.
Topics: Amantadine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine Agents; Dopamine Agonists; Dystonia; Globus Pallidus; Humans; Indans; Levodopa; Nerve Degeneration; Piperidines; Substantia Nigra; Supranuclear Palsy, Progressive | 2005 |
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Fungicides, Industrial; Herbicides; Immunohistochemistry; Levodopa; Male; Maneb; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Nerve Degeneration; Neuroprotective Agents; Paraquat; Parkinson Disease, Secondary; Phytotherapy; Plant Roots; Polygonum; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Degeneration; Nociceptin; Opioid Peptides; Parkinson Disease; Rats; Rats, Sprague-Dawley; Synaptic Transmission | 2005 |
Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
Topics: Animals; Animals, Newborn; Antibodies; Astrocytes; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cytoprotection; Dopamine; Dopamine Agents; Glial Cell Line-Derived Neurotrophic Factor; Hydrogen Peroxide; Levodopa; Nerve Degeneration; Neurons; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; RNA, Messenger; Substantia Nigra; Sympatholytics | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase | 2006 |
Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Mutant Strains; Motor Activity; Motor Skills; Nerve Degeneration; Parkinson Disease; Phosphorylation; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2006 |
Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments.
Topics: Aging; alpha-Synuclein; Amyloid beta-Protein Precursor; Animals; Axons; Corpus Striatum; Dopa Decarboxylase; Dopamine; Levodopa; Limbic System; Male; Nerve Degeneration; Phosphorylation; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Brain; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Tissue Donors | 2007 |
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Extremities; Levodopa; Male; Mesencephalon; Nerve Degeneration; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
The effect of subchronic, intermittent L-DOPA treatment on neuronal nitric oxide synthase and soluble guanylyl cyclase expression and activity in the striatum and midbrain of normal and MPTP-treated mice.
Topics: Animals; Blotting, Western; Cyclic GMP; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electrophoresis, Polyacrylamide Gel; Guanylate Cyclase; Immunohistochemistry; Levodopa; Mesencephalon; Mice; Mice, Inbred C57BL; Microdialysis; MPTP Poisoning; Neostriatum; Nerve Degeneration; Nerve Tissue Proteins; Nitric Oxide Synthase Type I; Phosphoric Diester Hydrolases; RNA, Messenger; Synaptosomes | 2007 |
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; Corpus Striatum; Denervation; Dopamine; Down-Regulation; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Functional Laterality; Helplessness, Learned; Levodopa; Male; Nerve Degeneration; Neurons; Oxidopamine; Rats; Rats, Wistar; Reaction Time; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2007 |
Excessive dopamine neuron loss in progressive supranuclear palsy.
Topics: Aged; Disease Progression; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Male; Nerve Degeneration; Neurons; Substantia Nigra; Supranuclear Palsy, Progressive | 2008 |
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cytosol; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Doxycycline; Functional Laterality; Levodopa; Mice; Mice, Transgenic; Microscopy, Electron, Transmission; Nerve Degeneration; Neurotoxins; Oxidative Stress; Prosencephalon; Psychomotor Performance; Silver Staining | 2008 |
Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Count; Cell Proliferation; Corpus Striatum; Denervation; Dopamine; Dopamine Plasma Membrane Transport Proteins; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
[Multi-infarct disorder presenting as corticobasal degeneration (DCB): vascular pseudo-corticobasal degeneration?].
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dementia, Multi-Infarct; Diagnosis, Differential; Disease Progression; Drug Resistance; Electroencephalography; Epilepsies, Myoclonic; Female; Functional Laterality; Gait Apraxia; Humans; Hypertension; Levodopa; Magnetic Resonance Imaging; Middle Aged; Nerve Degeneration; Neurologic Examination; Parkinson Disease; Phenotype | 2007 |
Deterioration of axonal membranes induced by phenolic pro-oxidants. Roles of superoxide radicals and hydrogen peroxide.
Topics: Animals; Astacoidea; Axons; Catalase; Electric Conductivity; Electric Stimulation; Hydrogen Peroxide; Hydroxydopamines; Levodopa; Nerve Degeneration; Oxidopamine; Superoxide Dismutase; Superoxides | 1984 |
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Topics: Animals; Brain; Catalase; Catecholamines; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Levodopa; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Selegiline; Superoxide Dismutase; Superoxides | 1983 |
[L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Atrophy; Brain Diseases; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1981 |
"Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study.
Topics: Aged; Corpus Striatum; Diagnosis, Differential; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Substantia Nigra | 1995 |
L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
Topics: Aged; Aged, 80 and over; Brain; Female; Humans; Levodopa; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Nerve Degeneration; Neural Pathways; Parkinson Disease; Putamen; Substantia Nigra | 1995 |
Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa.
Topics: Animals; Corpus Striatum; Culture Techniques; Dopamine; Electron Spin Resonance Spectroscopy; Free Radicals; Hydroxides; Hydroxyl Radical; Levodopa; Male; Mice; Mice, Inbred ICR; Microscopy, Electron; Nerve Degeneration; Receptors, Dopamine; Subcellular Fractions; Substantia Nigra; Superoxides; Thiobarbiturates | 1993 |
Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.
Topics: Adult; Aged; Brain; Brain Diseases; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Putamen; Radiography; Receptors, Dopamine D1; Tomography, Emission-Computed | 1993 |
Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Autoradiography; Basal Ganglia; Brain; Cell Death; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Nerve Degeneration; Neurons; Parkinson Disease; Radioligand Assay; Receptors, Transferrin; Reference Values | 1995 |
Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Topics: Animals; Antioxidants; Antiparkinson Agents; Apoptosis; Cell Count; Cell Survival; Cells, Cultured; Chick Embryo; Corpus Striatum; Cycloheximide; Dactinomycin; Flow Cytometry; Ganglia, Sympathetic; Humans; Levodopa; Microscopy, Fluorescence; Nerve Degeneration; Neurons; Parkinson Disease; Substantia Nigra | 1997 |
Mitochondrial respiratory chain function in multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Atrophy; Blood Platelets; Brain; Citrate (si)-Synthase; Culture Techniques; Electron Transport; Humans; Levodopa; Middle Aged; Mitochondria; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1997 |
Midbrain tremor and hypertrophic olivary degeneration after pontine hemorrhage.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antiparkinson Agents; Cerebral Hemorrhage; Clonazepam; Electric Stimulation; Electrodes, Implanted; Humans; Hypertrophy; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Nerve Degeneration; Neural Pathways; Olivary Nucleus; Pons; Propranolol; Thalamus; Tremor | 1997 |
Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture.
Topics: Age Factors; Animals; Animals, Newborn; Cell Count; Cell Culture Techniques; Cell Survival; Cells, Cultured; Dopamine Agents; Fluorescent Antibody Technique; Humans; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Neurons; Quinones; Superoxide Dismutase; Transgenes | 1997 |
Hereditary form of parkinsonism--dementia.
Topics: Adult; Antiparkinson Agents; Choline O-Acetyltransferase; Dementia; Dopamine; Family Health; Female; Genes, Dominant; Hippocampus; Homovanillic Acid; Humans; Levodopa; Lewy Bodies; Locus Coeruleus; Male; Middle Aged; Neostriatum; Nerve Degeneration; Neuropsychological Tests; Parkinson Disease; Pedigree; Substantia Innominata; Substantia Nigra; Temporal Lobe; Tomography, Emission-Computed | 1998 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Levodopa; Male; Motor Neurons; Nerve Degeneration; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Phosphoserine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serine; Sulfonamides; Sympatholytics | 1999 |
The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Dopamine; Female; Fructose-Bisphosphate Aldolase; Humans; In Situ Hybridization; Levodopa; Male; Middle Aged; Nerve Degeneration; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Time Factors; Transcription, Genetic; Tubulin; Tyrosine 3-Monooxygenase | 1999 |
Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.
Topics: Animals; Biological Transport; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Extracellular Space; Levodopa; Male; Microdialysis; Nerve Degeneration; Oxidopamine; Piperazines; Rats; Rats, Sprague-Dawley; Sympathomimetics; Tetrodotoxin | 1999 |
Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Antisense Elements (Genetics); Autoreceptors; Bromocriptine; Cell Survival; Cells, Cultured; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Fetus; Fluoresceins; Free Radicals; Gene Expression; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Sulpiride; Tyrosine 3-Monooxygenase | 1999 |
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area | 1999 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Diagnosis, Differential; Disease Models, Animal; Dopamine; Levodopa; Macaca fascicularis; Male; Multiple System Atrophy; Nerve Degeneration; Neurotoxins; Nitro Compounds; Parkinson Disease, Secondary; Propionates; Striatonigral Degeneration | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
DOPA cyclohexyl ester, a competitive DOPA antagonist, protects glutamate release and resultant delayed neuron death by transient ischemia in hippocampus CA1 of conscious rats.
Topics: Animals; Brain Ischemia; Cell Death; Dihydroxyphenylalanine; Glutamic Acid; Hippocampus; Levodopa; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Organ Culture Techniques; Rats; Rats, Wistar; Reperfusion Injury | 2001 |
Chronic autonomic failure with postural hypotension.
Topics: Autonomic Nervous System; Blood Pressure; Bromocriptine; Cardiovascular System; Chronic Disease; Fludrocortisone; Humans; Hypotension, Orthostatic; Levodopa; Nerve Degeneration; Nervous System Diseases; Pressoreceptors | 1979 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
L-dopa induced dyskinesias in asymmetrical parkinsonism.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Pathways; Parkinson Disease | 1979 |
Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
Topics: Animals; Apomorphine; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Piperazines; Rats; Receptors, Dopamine; Stereotyped Behavior; Stimulation, Chemical | 1976 |
Involvement of alpha-adrenergic receptors at different levels of the central nervous system in the regulation of blood pressure and heart frequency.
Topics: Animals; Blood Pressure; Central Nervous System; Clonidine; Dopamine; Heart Rate; Hydroxydopamines; Levodopa; Nerve Degeneration; Neurons; Norepinephrine; Pentobarbital; Rats; Receptors, Adrenergic; Serotonin | 1975 |
Dopaminergic supersensitivity in parkinsonism.
Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Nerve Degeneration; Norepinephrine; Parkinson Disease; Psychoses, Substance-Induced; Serotonin; Tryptophan; Tyrosine | 1975 |
[Supranuclear progressive paralysis (or oculo-facial-cervical dystonia)].
Topics: Aged; Bulbar Palsy, Progressive; Cerebral Cortex; Cranial Nerves; Demyelinating Diseases; Facial Paralysis; Female; Humans; Levodopa; Male; Middle Aged; Neck; Nerve Degeneration; Ophthalmoplegia; Reticular Formation | 1975 |
Behavioral correlates of dopaminergic supersensitivity.
Topics: Animals; Animals, Newborn; Apomorphine; Behavior; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Motor Activity; Nerve Degeneration; Rats; Receptors, Drug; Stereotyped Behavior; Substantia Nigra; Tranylcypromine; Tyrosine | 1975 |
Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa.
Topics: Animals; Behavior, Animal; Histocytochemistry; Injections, Intraventricular; Levodopa; Male; Nerve Degeneration; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Substantia Nigra; Tremor; Tyrosine 3-Monooxygenase | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Topics: Adult; Aged; Caudate Nucleus; Corpus Striatum; Humans; Levodopa; Middle Aged; Nerve Degeneration; Parkinson Disease; Putamen; Raclopride; Receptors, Dopamine; Salicylamides; Substantia Nigra; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1992 |
Case report: autonomic postganglionic denervation--sural nerve and saphenous vein biopsy.
Topics: Adult; Catecholamines; Denervation; Dopamine; Hormones; Humans; Levodopa; Microscopy, Electron; Nerve Degeneration; Nervous System Diseases; Saphenous Vein; Sural Nerve | 1992 |
L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Fenfluramine; Hippocampus; Levodopa; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Nervous System Diseases; p-Chloroamphetamine; Rats; Rats, Inbred Strains; Serotonin | 1991 |
L-dopa stimulates the release of [3H]gamma-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Benzazepines; Brain Chemistry; Dopamine Antagonists; gamma-Aminobutyric Acid; Hydrazines; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Nerve Degeneration; Oxidopamine; Potassium; Rats; Rats, Inbred Strains; Sulpiride; Sympathectomy, Chemical | 1991 |
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Topics: Adult; Aged; Carbidopa; Disability Evaluation; Dominance, Cerebral; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1989 |
Clinical and neuropathological study of a familial case of juvenile parkinsonism.
Topics: Adult; Brain; Cerebral Cortex; Female; Humans; Inclusion Bodies; Levodopa; Locus Coeruleus; Microscopy, Electron; Nerve Degeneration; Neurons; Parkinson Disease; Substantia Nigra | 1988 |
Bromocriptine therapy in striatonigral degeneration.
Topics: Aged; Bromocriptine; Humans; Levodopa; Male; Nerve Degeneration; Parkinson Disease, Secondary; Putamen; Substantia Nigra | 1988 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |